8-K Announcements
6Material company update
Mar 12, 2026·SEC
Material company update
Jan 29, 2026·SEC
Material company update
Jan 22, 2026·SEC
Erasca, Inc.(ERAS)Earnings, Financials & Key Ratios
ERAS•NASDAQ
$10.90
$3.09B mkt cap·Price updated May 6, 2026
AboutErasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.Show more
- Revenue$0
- EBITDA-$176M-27.6%
- Net Income-$162M-29.3%
- EPS (Diluted)-0.69+16.9%
- ROE-43.68%-27.2%
- ROIC-39.2%+14.6%
- Debt/Equity0.12-30.5%
ERAS Key Insights
Erasca, Inc. (ERAS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 98 (top 2%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 55.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ERAS Price & Volume
Erasca, Inc. (ERAS) stock price & volume — 10-year historical chart
Loading chart...
ERAS Growth Metrics
Erasca, Inc. (ERAS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM19.75%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM45.78%
Return on Capital
10 Years-55.05%
5 Years-61.02%
3 Years-43.07%
Last Year-42.74%
ERAS Recent Earnings
Erasca, Inc. (ERAS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
Mar 12, 2026EPS
$0.10
Est $0.11
+9.1%
Revenue
—
Q4 2025
Nov 12, 2025EPS
$0.11
Est $0.11
+0.0%
Revenue
—
Q3 2025
Aug 12, 2025EPS
$0.12
Est $0.12
+0.0%
Revenue
—
Q2 2025
May 13, 2025EPS
$0.11
Est $0.12
+8.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 12, 2026 | $0.10vs $0.11+9.1% | — |
| Q4 2025 | Nov 12, 2025 | $0.11vs $0.11+0.0% | — |
| Q3 2025 | Aug 12, 2025 | $0.12vs $0.12+0.0% | — |
| Q2 2025 | May 13, 2025 | $0.11vs $0.12+8.3% | — |
Based on last 12 quarters of dataView full earnings history →
ERAS Peer Comparison
Erasca, Inc. (ERAS) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RVMD | 32.12B | 151.07 | -25.39 | -83.22% | 0.10 | |||
 NUVL | 6.92B | 104.26 | -26.53 | -45.12% | ||||
 TNGX | 3.21B | 23.62 | -27.15 | 48.29% | -162.85% | -50.3% | 0.10 | |
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ARQT | 3.02B | 24.17 | -185.92 | 91.34% | -0.57% | -1.41% | 0.03 |
Compare ERAS vs Peers
Erasca, Inc. (ERAS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ERAS Income Statement
Erasca, Inc. (ERAS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 829K | 2.64M | 3.73M | 0 | 832K |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | -829K▲ 0% | -2.64M▼ 218.6% | -3.73M▼ 41.3% | 0▲ 100.0% | -832K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | -218.58% | -41.31% | 100% | - |
| Operating Expenses | 13.29M | 109.25M | 124.05M | 244.81M | 137.79M | 179.59M | 143.18M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 3.68M | 7.96M | 22.62M | 32.99M | 37.7M | 41.73M | 37.95M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 9.62M | 101.3M | 73.92M | 112.46M | 103.82M | 115.36M | 95.73M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 27.52M | 99.36M | -3.73M | 22.5M | 2M |
| Operating Income | -13.29M▲ 0% | -109.25M▼ 721.8% | -124.88M▼ 14.3% | -247.45M▼ 98.1% | -141.53M▲ 42.8% | -179.59M▼ 26.9% | -144.01M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -721.81% | -14.31% | -98.15% | 42.81% | -26.89% | - |
| EBITDA | -12.98M | -108.71M | -124.05M | -244.81M | -137.79M | -175.78M | -140.82M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -737.28% | -14.11% | -97.34% | 43.71% | -27.57% | 18.99% |
| D&A (Non-Cash Add-back) | 310K | 540K | 829K | 2.64M | 3.73M | 3.81M | 3.2M |
| EBIT | -13.29M | -37.51M | -122.76M | -242.81M | -125.04M | -157.09M | -129.1M |
| Net Interest Income | 1.3M | 336K | 190K | -196.46M | 16.71M | 20.09M | 18.32M |
| Interest Income | 1.3M | 336K | 190K | 4.9M | 16.71M | 20.09M | 18.32M |
| Interest Expense | 0 | 0 | 0 | 201.36M | 0 | 0 | 0 |
| Other Income/Expense | 1.25M | 7.59M | 2.12M | 4.64M | 16.48M | 17.94M | 16.33M |
| Pretax Income | -12.04M▲ 0% | -101.66M▼ 744.4% | -122.76M▼ 20.8% | -242.81M▼ 97.8% | -125.04M▲ 48.5% | -161.65M▼ 29.3% | -127.69M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -12.04M▲ 0% | -101.66M▼ 744.4% | -122.76M▼ 20.8% | -242.81M▼ 97.8% | -125.04M▲ 48.5% | -161.65M▼ 29.3% | -127.69M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -744.35% | -20.76% | -97.78% | 48.5% | -29.28% | 19.75% |
| Net Income (Continuing) | -12.04M | -101.66M | -122.76M | -242.81M | -125.04M | -161.65M | -127.69M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.10▲ 0% | -0.85▼ 750.0% | -1.03▼ 21.2% | -1.99▼ 93.2% | -0.83▲ 58.3% | -0.69▲ 16.9% | -0.45▲ 0% |
| EPS Growth % | - | -750% | -21.18% | -93.2% | 58.29% | 16.87% | 45.78% |
| EPS (Basic) | -0.10 | -0.85 | -1.03 | -1.99 | -0.83 | -0.69 | - |
| Diluted Shares Outstanding | 118.96M | 118.96M | 119.1M | 122.02M | 150.18M | 233.82M | 283.68M |
| Basic Shares Outstanding | 118.96M | 118.96M | 119.1M | 122.02M | 150.18M | 233.82M | 283.68M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
ERAS Balance Sheet
Erasca, Inc. (ERAS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 51.12M | 119.99M | 420.02M | 444.5M | 320.68M | 308.79M | 299.93M |
| Cash & Short-Term Investments | 50.37M | 118.7M | 414.48M | 435.62M | 312.35M | 298.31M | 288.4M |
| Cash Only | 29.58M | 65.38M | 360.49M | 284.22M | 93.08M | 67.74M | 70.23M |
| Short-Term Investments | 20.79M | 53.33M | 53.99M | 151.4M | 219.28M | 230.57M | 218.17M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 2.3M | 2.9M |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 1.29M | 100K | 748K | 1.1M | 8.18M | 8.63M |
| Total Non-Current Assets | 4.39M | 4.83M | 81.4M | 70.41M | 74.62M | 193.73M | 120.48M |
| Property, Plant & Equipment | 4.33M | 4.07M | 33.31M | 65.23M | 60.19M | 48.54M | 44.12M |
| Fixed Asset Turnover | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 312K | 44.77M | 2M | 10.05M | 142.16M | 409.54M |
| Other Non-Current Assets | 56K | 451K | 3.32M | 3.18M | 4.38M | 3.03M | 10.61M |
| Total Assets | 55.51M▲ 0% | 124.83M▲ 124.9% | 501.42M▲ 301.7% | 514.91M▲ 2.7% | 395.3M▼ 23.2% | 502.53M▲ 27.1% | 420.4M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 124.86% | 301.69% | 2.69% | -23.23% | 27.13% | 18.68% |
| Total Current Liabilities | 2.75M | 13.68M | 26.22M | 48.69M | 26.16M | 31.39M | 28.71M |
| Accounts Payable | 1.38M | 878K | 4.68M | 23.05M | 2M | 468K | 3.03M |
| Days Payables Outstanding | - | - | 2.06K | 3.19K | 195.61 | - | 814.01 |
| Short-Term Debt | 0 | 877K | 0 | 0 | 0 | 0 | 4.88M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 447K | 9.51M | 4.16M | 2.33M | 10.78M | 0 | 11.86M |
| Current Ratio | 18.59x | 8.77x | 16.02x | 9.13x | 12.26x | 9.84x | 9.84x |
| Quick Ratio | 18.59x | 8.77x | 16.02x | 9.13x | 12.26x | 9.84x | 9.84x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 66.37M | 3.72M | 18.66M | 54.37M | 52.45M | 47.63M | 43.8M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 2.96M | 2.11M | 18.51M | 53.79M | 51.89M | 47.27M | 181.41M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 63.4M | 1.61M | 158K | 573K | 566K | 362K | 1.27M |
| Total Liabilities | 69.12M | 17.4M | 44.89M | 103.06M | 78.61M | 79.03M | 72.52M |
| Total Debt | 3.69M | 2.99M | 18.79M | 55.1M | 55.86M | 51.89M | 48.29M |
| Net Debt | -25.89M | -62.39M | -341.7M | -229.12M | -37.22M | -15.85M | -21.94M |
| Debt / Equity | - | 0.03x | 0.04x | 0.13x | 0.18x | 0.12x | 0.12x |
| Debt / EBITDA | - | - | - | - | - | - | -0.34x |
| Net Debt / EBITDA | - | - | - | - | - | - | 0.16x |
| Interest Coverage | - | - | - | -1.23x | - | - | - |
| Total Equity | -13.6M▲ 0% | 107.42M▲ 889.6% | 456.53M▲ 325.0% | 411.85M▼ 9.8% | 316.69M▼ 23.1% | 423.5M▲ 33.7% | 347.89M▲ 0% |
| Equity Growth % | - | 889.63% | 324.99% | -9.79% | -23.11% | 33.73% | 32.07% |
| Book Value per Share | -0.11 | 0.90 | 3.83 | 3.38 | 2.11 | 1.81 | 1.23 |
| Total Shareholders' Equity | -13.6M | 107.42M | 456.53M | 411.85M | 316.69M | 423.5M | 347.89M |
| Common Stock | 3K | 3K | 12K | 15K | 15K | 28K | 28K |
| Retained Earnings | -13.74M | -115.4M | -238.17M | -480.97M | -606.01M | -767.66M | -863.12M |
| Treasury Stock | -124K | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 11K | 2K | -162K | -1.04M | 77K | 405K | 649K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ERAS Cash Flow Statement
Erasca, Inc. (ERAS) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -10.38M | -32.69M | -79.6M | -103.26M | -101.22M | -109.42M | -109.42M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -214.95% | -143.53% | -29.73% | 1.98% | -8.1% | 39.05% |
| Net Income | -12.04M | -101.66M | -122.76M | -242.81M | -125.04M | -161.65M | -127.69M |
| Depreciation & Amortization | 310K | 540K | 829K | 2.64M | 3.73M | 3.81M | 3.2M |
| Stock-Based Compensation | 122K | 797K | 8.33M | 20.11M | 26.23M | 26.97M | 6.71M |
| Deferred Taxes | 0 | 0 | -1.51M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -483K | 64.35M | 27.81M | 101.01M | -6.95M | 19.72M | 23.07M |
| Working Capital Changes | 1.71M | 3.29M | 7.71M | 15.79M | 813K | 1.74M | -3.6M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.17M | -380K | 1.34M | 676K | -886K | -1.53M | 624K |
| Cash from Investing | -20.89M | -71.2M | -64.59M | -71.08M | -91.22M | -156.62M | 98.33M |
| Capital Expenditures | -597K | -947K | -18.89M | -16.55M | -1.77M | -60K | -119K |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 7.68M | 4M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | -37.74M | -7.68M | -4M | -20M | -22.5M | -9.5M |
| Cash from Financing | 16.86M | 139.99M | 439.4M | 98.08M | 1.29M | 240.7M | 1.32M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1.32M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 3.02M | 3M | 2.82M | 0 | 1.64M | 0 |
| Net Change in Cash | -14.4M▲ 0% | 36.1M▲ 350.7% | 295.21M▲ 717.6% | -76.27M▼ 125.8% | -191.14M▼ 150.6% | -25.34M▲ 86.7% | 1.34M▲ 0% |
| Free Cash Flow | -10.97M▲ 0% | -71.38M▼ 550.4% | -98.48M▼ 38.0% | -119.81M▼ 21.7% | -102.99M▲ 14.0% | -131.98M▼ 28.1% | -98.43M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | -550.37% | -37.98% | -21.66% | 14.04% | -28.14% | 10.34% |
| FCF per Share | -0.09 | -0.60 | -0.83 | -0.98 | -0.69 | -0.56 | -0.56 |
| FCF Conversion (FCF/Net Income) | 0.86x | 0.32x | 0.65x | 0.43x | 0.81x | 0.68x | 0.77x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 13K | 69K | 0 | 0 | 0 | 0 | 0 |
ERAS Key Ratios
Erasca, Inc. (ERAS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -216.72% | -43.54% | -55.92% | -34.33% | -43.68% | -36.7% |
| Return on Invested Capital (ROIC) | -2961.83% | -117.18% | -124.74% | -45.93% | -39.2% | -39.2% |
| Debt / Equity | 0.03x | 0.04x | 0.13x | 0.18x | 0.12x | 0.12x |
| Interest Coverage | - | - | -1.23x | - | - | - |
| FCF Conversion | 0.32x | 0.65x | 0.43x | 0.81x | 0.68x | 0.77x |
ERAS SEC Filings & Documents
Erasca, Inc. (ERAS) SEC filings — annual & quarterly reports (10-K, 10-Q)
ERAS Frequently Asked Questions
Erasca, Inc. (ERAS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Erasca, Inc. (ERAS) grew revenue by 0.0% over the past year. Growth has been modest.
Erasca, Inc. (ERAS) reported a net loss of $127.7M for fiscal year 2024.
Dividend & Returns
Erasca, Inc. (ERAS) has a return on equity (ROE) of -43.7%. Negative ROE indicates the company is unprofitable.
Erasca, Inc. (ERAS) had negative free cash flow of $98.4M in fiscal year 2024, likely due to heavy capital investments.
Explore More ERAS
Erasca, Inc. (ERAS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates